柳氮磺吡啶是免疫抑制剂吗？柳氮磺吡啶的功效和作用

The antirheumatic effect of sulfasalazine may be produced by sulfapyridine inhibiting certain antigenic substances in the intestine, thereby inhibiting the immune process of ankylosing spondylitis and rheumatoid arthritis. Sulfasalazine has little absorption from the gastrointestinal tract, has a special affinity for connective tissue, and releases sulfapyridine from the connective tissue of the intestinal wall. Is it an immunosuppressant?

Indications for sulfasalazine

Sulfasalazine is an azo compound of salicylic acid and sulfapyridine, which has antibacterial, antirheumatic and immunosuppressive effects. Sulfasalazine is an antibacterial drug that is mainly used clinically to treat intestinal diseases such as ulcerative colitis. However, studies have found that the mechanism of action of sulfasalazine also has a certain effect in the treatment of rheumatoid arthritis. In fact, the main treatment principles for the treatment of enteritis and rheumatoid arthritis are anti-inflammatory and antibacterial, and sulfasalazine has the effect in this area, so it has a therapeutic effect.

Efficacy and effects of sulfasalazine

It is broken down by bacteria in the intestine into sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA). SP has a weak antibacterial effect. It mainly acts as a carrier in drug molecules, preventing the absorption of 5-ASA in the stomach and duodenum. Only under alkaline conditions in the intestine, intestinal microorganisms rupture the diazo bonds and release the active ingredients.

To explore the clinical effect of endoscopic administration combined with oral administration of sulfasalazine enteric-coated tablets in the treatment of ulcerative colitis. 80 patients with ulcerative colitis were selected and randomly divided into groups: 40 patients in the control group were treated with sulfasalazine enteric-coated tablets alone, and 40 patients in the observation group were treated with endoscopic administration combined with sulfasalazine enteric-coated tablets. Compare the albumin, hemoglobin and treatment effectiveness of the two groups before and after treatment. Results: Before treatment, there was no significant difference in albumin and hemoglobin between the two groups (P>0.05). After treatment, the albumin and hemoglobin indicators of the observation group were significantly better than those of the control group (P<0.05). The total effective rate of clinical treatment in the observation group was 97.5%, and that in the control group was 80.0%. There was a significant difference between the two groups (P<0.05). Conclusion: Endoscopic administration combined with oral administration of sulfasalazine enteric-coated tablets can effectively improve the patient's albumin and hemoglobin indexes in patients with ulcerative colitis, and the therapeutic effect is good. This method can be used clinically.

The above is an introduction to sulfasalazine. If patients have other questions about the drug (such as drug prices, purchase channels, etc.), they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related hot articles